Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.

Date publication

mars 2020

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel

Tous les auteurs :
Negrier S, Rioux-Leclercq N, Ferlay C, Gross-Goupil M, Gravis G, Geoffrois L, Chevreau C, Boyle H, Rolland F, Blanc E, Ravaud A, Dermeche S, Flechon A, Albiges L, Pérol D, Escudier B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32146304

Résumé

Papillary renal cell carcinoma (PRCC) represents 10%-15% of renal carcinomas. No standard treatments exist for metastatic PRCC (mPRCC) patients. Axitinib is indicated as second-line treatment in metastatic clear cell renal carcinoma, and we aim to assess the efficacy of this vascular endothelial growth factor receptor inhibitor in front line for mPRCC.

Mots clés

Advanced renal cancer, Papillary renal cell carcinoma, Targeted therapy, Tyrosine kinase, VEGF inhibitor, Vascular endothelial growth factor

Référence

Eur. J. Cancer. 2020 Mar 5;129:107-116